Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Systemic Adjuvant Therapy in Early HER2+ Breast Cancer: Escalating w/New HER2 Targeted Tx (Neratinib, Pertuzumab, T-DMI1), and When to De-Escalate?

0 views
December 4, 2019
Comments 0
Login to view comments. Click here to Login